CR20220523A - Anticuerpos anti-sea de muc1 - Google Patents

Anticuerpos anti-sea de muc1

Info

Publication number
CR20220523A
CR20220523A CR20220523A CR20220523A CR20220523A CR 20220523 A CR20220523 A CR 20220523A CR 20220523 A CR20220523 A CR 20220523A CR 20220523 A CR20220523 A CR 20220523A CR 20220523 A CR20220523 A CR 20220523A
Authority
CR
Costa Rica
Prior art keywords
muc1
antibodies
sea antibodies
sea
bind
Prior art date
Application number
CR20220523A
Other languages
English (en)
Inventor
Daniel Rubinstein
Daniel Wreschner
Original Assignee
Univ Ramot
Biomodifying Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot, Biomodifying Llc filed Critical Univ Ramot
Publication of CR20220523A publication Critical patent/CR20220523A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/852—Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Optics & Photonics (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)

Abstract

La presente invención proporciona anticuerpos monoclonales aislados que se unen al dominio SEA de MUC1. La invención se refiere, además, al uso de estos anticuerpos en métodos terapéuticos y de diagnóstico.
CR20220523A 2020-03-18 2021-03-11 Anticuerpos anti-sea de muc1 CR20220523A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062991077P 2020-03-18 2020-03-18
PCT/IL2021/050269 WO2021186427A1 (en) 2020-03-18 2021-03-11 Anti- muc1-sea antibodies

Publications (1)

Publication Number Publication Date
CR20220523A true CR20220523A (es) 2023-01-23

Family

ID=75439163

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220523A CR20220523A (es) 2020-03-18 2021-03-11 Anticuerpos anti-sea de muc1

Country Status (18)

Country Link
US (1) US20230085269A1 (es)
EP (1) EP4087879A1 (es)
JP (1) JP2023517754A (es)
KR (1) KR20220161267A (es)
CN (1) CN115667312A (es)
AU (1) AU2021239078A1 (es)
BR (1) BR112022018629A2 (es)
CA (1) CA3171531A1 (es)
CL (1) CL2022002520A1 (es)
CO (1) CO2022014726A2 (es)
CR (1) CR20220523A (es)
CU (1) CU20220055A7 (es)
DO (1) DOP2022000193A (es)
EC (1) ECSP22080687A (es)
IL (1) IL296572A (es)
MX (1) MX2022011553A (es)
PE (1) PE20230602A1 (es)
WO (1) WO2021186427A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2595778A1 (en) * 2005-01-28 2006-08-03 Ramot At Tel Aviv University, Ltd. Anti-muc1 .alpha..beta. antibodies
CN111201240B (zh) * 2017-03-21 2024-03-22 株式会社菲特伦 特异性地结合muc1的抗体及其用途

Also Published As

Publication number Publication date
ECSP22080687A (es) 2022-12-30
US20230085269A1 (en) 2023-03-16
AU2021239078A1 (en) 2022-08-11
KR20220161267A (ko) 2022-12-06
MX2022011553A (es) 2023-01-04
BR112022018629A2 (pt) 2023-03-07
IL296572A (en) 2022-11-01
JP2023517754A (ja) 2023-04-26
CL2022002520A1 (es) 2023-03-10
WO2021186427A1 (en) 2021-09-23
PE20230602A1 (es) 2023-04-10
CN115667312A (zh) 2023-01-31
CA3171531A1 (en) 2021-09-23
CU20220055A7 (es) 2023-06-13
EP4087879A1 (en) 2022-11-16
CO2022014726A2 (es) 2023-02-16
DOP2022000193A (es) 2023-03-23

Similar Documents

Publication Publication Date Title
PH12020552116A1 (en) Bispecific anti-psma x anti-cd28 antibodies and uses thereof
MX2020009121A (es) Uso de anticuerpos sirpa v1 antihumanos y procedimiento de produccion de anticuerpos anti-sirpa v1.
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
MY194764A (en) Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof
MX2021006971A (es) Anticuerpos anti-muc16 x anti-cd28 biespecificos y usos de estos.
CR20200467A (es) Agentes anticuerpos anti-cd25
EA201890785A1 (ru) Оптимизированные биспецифические анти-cd3 антитела и их применение
PH12020551930A1 (en) Anti-sirpa antibodies and methods of use thereof
EA202191580A1 (ru) Биспецифичные антитела анти-cd28 x анти-cd22 и их применение
MX2017001599A (es) Anticuerpos novedosos y sus usos.
PH12021550041A1 (en) Anti-sortilin antibodies and methods of use thereof
MX2021005761A (es) Anticuerpos anti-proteína alfa reguladora de señal (anti-sirpalfa) humanizados.
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
MX2021003673A (es) Anticuerpos anti-vsig4 humano y usos de los mismos.
MX2021012692A (es) Anticuerpos anti-mertk y sus metodos de uso.
EA202190235A1 (ru) Антитела к cd33 и способы их применения
WO2022051591A3 (en) Nectin-4 antibodies and uses thereof
EA201992316A1 (ru) Композиции и способы для диагностики рака предстательной железы
MX2020009902A (es) Anticuerpos con especificidad dual para pd-l1 y pd-l2 humanos y metodos de uso de los mismos.
MX2021011040A (es) Anticuerpos dirigidos contra c5ar.
MX2022004194A (es) Anticuerpos contra el receptor de virus de la polio (pvr) y usos de los mismos.
PH12020551451A1 (en) Anti-cd25 for tumour specific cell depletion
CR20220523A (es) Anticuerpos anti-sea de muc1
MX2022007919A (es) Proteinas de union al factor de crecimiento transformante receptor beta ii (tgf-beta-rii).
MX2021001604A (es) Tratamiento del cáncer con un anticuerpo.